We are L-Ornithine L-Aspartate CAS:3230-94-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
L-Ornithine L-Aspartate
An aspartate salt of L-ornithine. L-Ornithine L-aspartate has been shown to reduce blood ammonia concentrations by increasing ammonia detoxification in the liver and reducing the severity of hepatic encephalopathy in cirrhosis.
| Cas.No | 3230-94-2 |
| Assay | 98.0-101.0% |
| Description | White crystals or crystalline powder, odorless, slightly acid taste |
| Status | Infusion |
| Applications | Dietary Supplement |
| Packaging | 25kg&50kg |
| STORAGE |
Controlled room temperature in tight container. Keep in dark. |
SPECIFICATION AND PROCEDURE
|
State of solution (Transmittance) |
Not Less Than 98.0% |
| pH | 5.0～6.0 |
| Specific rotation[α]20D | +26.9～+28.9° |
| Ammonium (NH4) | Not More Than 0.020% |
| Chloride content (Cl) | Not More Than 0.020% |
| Sulfate (SO4) | Not More Than 0.020% |
| Iron (Fe) | Not More Than 10 ppm |
| Heavy metals (Pb) | Not More Than 10 ppm |
| Arsenic (As2O3) | Not More Than 1 ppm |
| Loss on drying | Not More Than 3.0% |
| Residue on ignition | Not More Than 0.20% |
| Related substances | Not More Than 0.4% |
| Endotoxin* | Less Than 6.0 EU/g |
| Assay (dry basis) | 98.0～101.0% |
· * The endotoxin-certified grade will be supplied on request.
Related News: API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.3-Chloro-1-propanol CAS:627-30-5 API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.clorhidrato de clorometilo CAS:22128-62-7 The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.2-cianoisonicotinato de metilo CAS:94413-64-6 The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.
| Product Name | |
|---|---|
| D-Valine | View Details |
| TRIPHENYL PHOSPHATE (TPP) | View Details |
| 2-Bromo-5-chloroanisole | View Details |